Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics [0.03%]
免疫检查点抑制剂增强瘤内治疗：多模式治疗理念的转变
B E Nelson,A Naing,S Fu et al.
B E Nelson et al.
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a cri...
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers [0.03%]
基于新抗原的肿瘤浸润性淋巴细胞(TIL)治疗晚期实体瘤或免疫检查点抑制剂耐药实体瘤的临床前数据和I期临床试验设计
J Palomero,V Galvao,I Creus et al.
J Palomero et al.
Background: Adoptive cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs) can mediate objective tumor regression in 28%-49% of metastatic melanoma patients. However, the efficacy of TIL therapy in ...
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma [0.03%]
肿瘤浸润淋巴细胞免疫疗法联合纳武单抗治疗晚期黑色素瘤患者的临床研究
D König,B Kasenda,M Sandholzer et al.
D König et al.
Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma but is not ...
W K Lim,N G Iyer
W K Lim
γδ T cells represent an 'unconventional' class of CD3+ lymphocytes with unique phenotypical and functional attributes that distinguishes them from their αβ T-cell receptor-expressing counterparts. Studies investigating the roles of γδ...
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy [0.03%]
作为癌症治疗的微型药房对嵌合抗原受体(CAR)T细胞进行装甲防护
C Carcopino,E Erdogan,M Henrich et al.
C Carcopino et al.
Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a powerful weapon in the fight against cancer. However, its efficacy is often hindered by challenges such as limited tumor penetration, antigen escape, and immune suppression wit...
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy [0.03%]
接受免疫治疗的患者的AXL和/或MITF黑色素瘤亚群的变化
M Willemsen,J Bulgarelli,S K Chauhan et al.
M Willemsen et al.
Background: Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the 'mixed responses' frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resist...
Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications [0.03%]
分析效应细胞的功能异质性以增强过继性细胞疗法的效果
A C Kiel Rasmussen,T M Hulen,D L Petersen et al.
A C Kiel Rasmussen et al.
Cellular effector function assays traditionally rely on bulk cell populations that mask complex heterogeneity and rare subpopulations. The Xdrop® droplet technology facilitates high-throughput compartmentalization of viable single cells or...
Region of interest localization, tissue storage time, and antibody binding density-a technical note on the GeoMx® Digital Spatial Profiler [0.03%]
感兴趣区域定位、组织储存时间和抗体结合密度——关于GeoMx® 数字空间剖析器的技术说明
S Böning,F Schneider,A-K Huber et al.
S Böning et al.
Background: Spatial biology is an emerging concept to interrogate tumor heterogeneity. The NanoString GeoMx® Digital Spatial Profiling (DSP) platform has become increasingly available. It combines high-plex analysis of p...
A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models [0.03%]
一种新型抗FGFR1单克隆抗体OM-RCA-01在肺癌模型中表现出强大的抗肿瘤活性并增强免疫检查点抑制剂的疗效
I Tsimafeyeu,P Makhov,D Ovcharenko et al.
I Tsimafeyeu et al.
Background: Fibroblast growth factor receptor 1 (FGFR1) plays a crucial role in carcinogenesis. Exploring the combination of the novel humanized monoclonal anti-FGFR1 antibody OM-RCA-01 and immunotherapy was intriguing du...
An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy [0.03%]
一种用于基于Vγ9Vδ2-T细胞免疫治疗的体外检测的人皮肤黑色素瘤器官型模型
E Michielon,L A King,T Waaijman et al.
E Michielon et al.
Background: Despite considerable advancements in cancer immunotherapy, advanced melanoma still presents a substantial clinical challenge. In an effort to explore treatment options, we examined the immunotherapeutic potent...